Cell Therapy News Volume 26.11 | Jun 30 2025

    0
    40







    2025-06-30 | CTN 26.10


    Cell Therapy News by STEMCELL Technologies
    Vol. 26.11 – 30 June, 2025
    TOP STORY

    AAV Mini-Dystrophin Gene Therapy for Duchenne Muscular Dystrophy: A Phase Ib Trial

    Pediatric ambulatory male participants with a genetic Duchenne muscular dystrophy diagnosis and receiving stable glucocorticoids received a single intravenous low-dose or high-dose fordadistrogene movaparvovec.
    [Nature Medicine]

    Full Article
    PUBLICATIONSListed by the impact factor of the journal

    An iPSC-Derived CD19/BCMA CAR-NK Therapy in a Patient with Systemic Sclerosis

    Researchers reported the first-in-human application of iPSC-derived CD19/BCMA dual-targeting CAR-NK cells in a patient with severe, diffuse cutaneous systemic sclerosis.
    [Cell]

    AbstractGraphical Abstract

    In Vivo CAR T Cell Generation to Treat Cancer and Autoimmune Disease

    Scientists reported a gene-delivery system to generate CAR-T cells in vivo by dosing of a CD8-targeted lipid nanoparticle carrying anti-CD19 CAR mRNA.
    [Science]

    Abstract

    OX40-Heparan Sulfate Binding Facilitates CAR T Cell Penetration into Solid Tumors in Mice

    The authors found that, in addition to OX40 ligand, OX40 can bind to heparan sulfate, a glycosaminoglycan highly expressed on various solid tumor cells.
    [Science Translational Medicine]

    Abstract

    AAV-Based Delivery of RNAi Targeting Ataxin-2 Improves Survival and Pathology in TDP-43 Mice

    Investigators showed that an AAV with potent motor neuron transduction delivering Atxn2-targeting miRNAs reduces Atxn2 throughout the central nervous system at doses 40x lower than published work.
    [Nature Communications]

    Full Article

    Engineered CD4 TCR T Cells with Conserved High-Affinity TCRs Targeting NY-ESO-1 for Advanced Cellular Therapies in Cancer

    Researchers screened HLA-DRB3*02:02 patients with melanoma for tumor-specific CD4 T cells and identified robust New York esophageal squamous cell carcinoma 1/HLA-DRB3*02:02 CD4 T cell activity in both peripheral blood and tumor tissue.
    [Science Advances]

    Full Article

    Targeted In Vivo Delivery of Genetic Medicines Utilizing an Engineered Lentiviral Vector Platform Results in CAR T and NK Cell Generation

    Investigators described the development of a lentiviral platform based on a novel, detargeted viral fusogen and a membrane-bound targeting moiety to enable in vivo targeted delivery of stably integrating genetic medicines without the need for lymphodepletion.
    [Molecular Therapy]

    AbstractFull ArticleGraphical Abstract

    Modified hTERT Promoters-Driven Purine Nucleoside Phosphorylase-Gene Therapy in Association with Chemo- and Targeted Therapy in the Context of Ovarian Cancer

    Researchers proposed an original ovarian cancer treatment through the use of two recently developed modified hTERT promoters: the mutated hTERT and the chimeric hTERT-CMV.
    [Cancer Gene Therapy]

    Abstract

    Sustained High Expression of Human FVII following AAV8-Mediated Gene Delivery in Mice

    The authors explored whether AAV mediated gene therapy can achieve durable and functional expression of human FVII in vivo.
    [Molecular Therapy-Methods & Clinical Development]

    AbstractFull ArticleGraphical Abstract
    REVIEWS

    Neurological Complications of CAR T Cell Therapy for Cancers

    Genetically engineered CAR T cells have emerged as a powerful treatment option in patients with B cell malignancies, but neurological adverse effects are common and hamper the success of such therapies.
    [Nature Reviews Neurology]

    Abstract

    Chimeric Antigen Receptor (CAR) T-Cell Therapy: Engineering Immune Cells To Treat Liver Diseases

    The authors present an overview of CAR technology’s fundamental principles and achievements, focusing on CAR-T cell applications in hepatic viral infections, autoimmune liver disease, and hepatobiliary tumors.
    [Journal of Hepatology]

    Full Article

    AAV for Ovarian Cancer Gene Therapy

    Scientists explore the potential of AAV vectors for gene therapy in ovarian cancer and examine rational gene therapy strategies by categorizing them based on target cells and target genes to determine the most effective approach for ovarian cancer treatment.
    [Cancer Gene Therapy]

    Full Article
    INDUSTRY AND POLICY NEWS

    STEMCELL Technologies Introduces STEMprepâ„¢ Tissue Dissociator System to Accelerate Research Discoveries

    To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation.
    [STEMCELL Technologies]

    Press Release

    U of T Engineering Researchers and Startup boutIQ Solutions Partner to Advance Heart Repair Therapies

    Professors Craig Simmons and Julie Audet, in collaboration with boutIQ solutions Inc., a University of Toronto (U of T) spinout company specializing in AI-driven media optimization, has been awarded a $421,000 research grant through the Stem Cell Network’s 2025 Research Funding Competition.
    [U of T Engineering News]

    Press Release
    FEATURED EVENT

    TERMIS EU 2025

    May 20-23, 2025
    Freiburg, Germany

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – CAR Treg Based Therapy

    UMass Chan Medical School – Worcester, Massachusetts, United States

    Postdoctoral Research Fellow – Pancreatic Cancer

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Scientist – Advanced Therapies Production

    King’s College London – London, England, United Kingdom

    Research Professor – Stem Cell and Developmental Biology

    KU Leuven – Leuven, Belgium

    Postdoctoral Researcher – Translational Interventional Oncology

    LMU Klinikum – Munich, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2